GlassScriptPhysician profile
Fredrick A Teixeira
NPI 1972552669
$3,735.27
in general payments reported to CMS, 2019-2025
34 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $486 · 2021: $327 · 2022: $541 · 2023: $738 · 2024: $546 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $877.63 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.53 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $314.58 | 2020-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $248.14 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $216.31 | 2020-2024 | Lynparza, Enhertu |
| Abbvie INC. | $214.26 | 2021-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $168.78 | 2019-2024 | Camzyos, Krazati, Opdivo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.77 | 2019-2020 | |
| Pfizer INC. | $160.00 | 2019-2025 | |
| Janssen Biotech, INC. | $112.98 | 2023-2025 | Darzalex, Tecvayli, Imbruvica |
| Incyte Corporation | $82.13 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Allergan, INC. | $75.30 | 2019-2020 | |
| Amgen INC. | $72.05 | 2019-2023 | Repatha |
| Exelixis INC. | $67.20 | 2023-2024 | Cabometyx |
| Portola Pharmaceuticals, LLC | $66.04 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $61.95 | 2021-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Vifor Pharma, INC. | $44.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.56 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $38.74 | 2024 | Orgovyx |
| Bioxcel Therapeutics, INC. | $32.67 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.44 | 2025 | Jardiance |
| Beone Medicines USA, INC. | $24.48 | 2025 | Brukinsa |
| Argenx US, INC. | $22.59 | 2023 | Vyvgart |
| Alkermes, INC. | $21.84 | 2019 | |
| Gilead Sciences, INC. | $21.81 | 2022 | |
| Eisai INC. | $21.36 | 2023 | |
| Beigene USA, INC. | $19.74 | 2024 | Brukinsa |
| Smith+Nephew, INC. | $18.27 | 2022 | |
| Rigel Pharmaceuticals, INC. | $17.37 | 2024 | Rezlidhia, Tavalisse |
| Otsuka America Pharmaceutical, INC. | $16.52 | 2019 | |
| Astellas Pharma US INC | $15.13 | 2024 | Xospata |
| Mallinckrodt Hospital Products INC. | $14.76 | 2025 | Terlivaz |
| Tetraphase Pharmaceuticals, INC. | $13.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Teixeira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.